{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15511.78","value":"-4357.5"},{"groupId":"OG001","spread":"10800.38","value":"-10179.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"For each participant, blood samples were assayed for NT-proBNP, comparing the participant's baseline value over time to assess reduced amyloidosis, as measured by a decrease in NT-proBNP. A decrease indicates cardiac enhancement. Results reported as nanograms/milliliter (ng/mL).","dispersionType":"Standard Deviation","groups":[{"description":"During the PETP, participants were administered CAEL-101 as an IV infusion over approximately 2 hours, in addition to SoC plasma cell dyscrasia treatment. All participants continued their double-blind treatment until LPI+18 months.\n\nAll participants had the option to enter into the OLEP, where they continued to receive CAEL-101 in addition to any SoC prescribed by a physician.","id":"OG000","title":"CAEL-101 + Plasma Cell Dyscrasia Treatment"},{"description":"During the PETP, participants were administered placebo as an IV infusion over approximately 2 hours, in addition to SoC plasma cell dyscrasia treatment. All participants continued their double-blind treatment until LPI+18 months.\n\nAll participants had the option to enter into the OLEP, where they continued to receive CAEL-101 in addition to any SoC prescribed by a physician.","id":"OG001","title":"Placebo + Plasma Cell Dyscrasia Treatment"}],"paramType":"MEAN","populationDescription":"Intent-to-Treat Set: all participants who were randomized. As prespecified, data collected and reported for Intent-to-Treat Set. Here, 'Overall Number of Participants Analyzed' signifies those participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 50","title":"Change From Baseline in N-Terminal Pro-B-type Natriuretic Peptide (NT-proBNP) in Blood Samples","type":"SECONDARY","unitOfMeasure":"ng/mL"}